Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Brainstorm Cell Therapeutics Stock Down 2.0 %

Shares of BCLI opened at $1.99 on Wednesday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89. The company’s fifty day moving average is $1.92 and its two-hundred day moving average is $2.97. The firm has a market cap of $11.35 million, a PE ratio of -0.41 and a beta of 0.29.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.